Accellta and Nano Dimension Team Up to 3D-Print Living Stem Cells

25.05.16

Bio Tech

Haifa, Israel — May 2016 — Accellta Ltd., an Israeli Biotech company that develops scalable stem-cell technologies, and Nano Dimension Ltd. (NASDAQ, TASE: NNDM), a global 3D-printing pioneer, achieved a breakthrough in 3D bioprinting of stem cells.

Together, the teams used Accellta’s suspension-culture system and Nano Dimension’s high-speed inkjet printing to print living stem cells in 3D. The printed cells stayed viable and formed accurate, layered structures. This result shows how biology and engineering can now work side by side.

As a result, the collaboration marks a new step toward functional tissue printing. It also proves that scalable cell production and precision printing can be combined to advance regenerative medicine.

“By joining forces, we turned a shared vision into reality,” said Dr. Itzchak Angel, CEO and Chairman of Accellta. “Our work brings the dream of printed tissues—and one day, printed organs—closer than ever.”

In addition, the companies are considering a joint venture to create affordable bioprinters for research and medical applications. Their goal is to make 3D bioprinting faster, simpler, and more accessible.

Moreover, the global bioprinting market continues to grow quickly. According to IDTechEx, it may reach $6 billion by 2024 as demand rises for cell-based tools in drug discovery, toxicity testing, and tissue engineering.

Ultimately, this collaboration shows how Accellta 3D bioprinting can help shape the future of regenerative medicine innovation, connecting Israeli science with global technology leadership.

Accellta’s Technology in Bioprinting

Accellta’s proprietary cell-culture technology provides the missing link between biology and bioprinting. Its 3D suspension platform enables the rapid growth of billions of high-quality stem cells in a serum-free, xeno-free environment — ideal for producing consistent, viable bio-inks. Unlike traditional methods that rely on scaffolds or carriers, Accellta’s process supports scalable differentiation of stem cells into target tissues with precision and reproducibility. This combination of speed, purity, and scalability makes Accellta 3D bioprinting a key enabler for printing complex living structures, paving the way for breakthroughs in regenerative medicine, drug testing, and tissue engineering.